Lisa M Prach1, Lisa Pascopella, Pennan M Barry, Jennifer Flood, Travis C Porco, Philip C Hopewell, John Z Metcalfe. 1. aCenter for AIDS Prevention Studies (CAPS), University of California, San Francisco bTuberculosis Control Branch, Division of Communicable Disease Control, Center for Infectious Diseases, California Department of Public Health, Richmond cF.I. Proctor Foundation, University of California, San Francisco dCurry International Tuberculosis Center, Division of Pulmonary and Critical Care Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA.
Abstract
OBJECTIVE: Rifampin monoresistant tuberculosis (RMR-TB) is increasingly identified because of scale-up of rapid molecular tests. The longitudinal association of RMR-TB, multidrug-resistant TB (MDR-TB), and HIV/AIDS is incompletely described. METHODS: We examined clinical characteristics and treatment outcomes of patients with RMR-TB, isoniazid monoresistant TB (IMR-TB), MDR-TB, and drug-susceptible TB during a 16-year period (1993-2008) in California. TB cases were cross-matched with the state HIV/AIDS registry, and HIV prevalence denominators modeled using nonparametric backcalculation. RESULTS: Of 42,582 TB cases, 178 (0.4%), 3469 (8.1%), and 635 (1.5%) were RMR-TB, IMR-TB, and MDR-TB, respectively. From the pre-HAART (1993-1996) to HAART (2005-2008) era, RMR-TB rates declined rapidly (12.0 vs. 0.5 per 100,000) among patients with HIV infection. The proportion of patients for whom rifampin resistance indicated RMR-TB (rather than MDR-TB) decreased from 31% [95% confidence interval (CI) 26-38%] to 11% (95% CI 5-19%). In multivariate analysis controlling for HIV coinfection and other covariates, patients with RMR-TB were twice as likely to die as patients with drug-sensitive TB (relative risk 1.94, 95% CI 1.40-2.69). CONCLUSION: RMR-TB/HIV rates declined substantially over time in association with improved TB control and HIV control in California. Mortality among patients with RMR-TB was high, even after adjusting for HIV status.
OBJECTIVE:Rifampin monoresistant tuberculosis (RMR-TB) is increasingly identified because of scale-up of rapid molecular tests. The longitudinal association of RMR-TB, multidrug-resistant TB (MDR-TB), and HIV/AIDS is incompletely described. METHODS: We examined clinical characteristics and treatment outcomes of patients with RMR-TB, isoniazid monoresistant TB (IMR-TB), MDR-TB, and drug-susceptible TB during a 16-year period (1993-2008) in California. TB cases were cross-matched with the state HIV/AIDS registry, and HIV prevalence denominators modeled using nonparametric backcalculation. RESULTS: Of 42,582 TB cases, 178 (0.4%), 3469 (8.1%), and 635 (1.5%) were RMR-TB, IMR-TB, and MDR-TB, respectively. From the pre-HAART (1993-1996) to HAART (2005-2008) era, RMR-TB rates declined rapidly (12.0 vs. 0.5 per 100,000) among patients with HIV infection. The proportion of patients for whom rifampin resistance indicated RMR-TB (rather than MDR-TB) decreased from 31% [95% confidence interval (CI) 26-38%] to 11% (95% CI 5-19%). In multivariate analysis controlling for HIV coinfection and other covariates, patients with RMR-TB were twice as likely to die as patients with drug-sensitive TB (relative risk 1.94, 95% CI 1.40-2.69). CONCLUSION: RMR-TB/HIV rates declined substantially over time in association with improved TB control and HIV control in California. Mortality among patients with RMR-TB was high, even after adjusting for HIV status.
Authors: Qiang Xia; Janice L Westenhouse; Alan F Schultz; Atsuko Nonoyama; William Elms; Nancy Wu; Lisette Tabshouri; Juan D Ruiz; Jennifer M Flood Journal: Health Informatics J Date: 2011-03 Impact factor: 2.681
Authors: Prema Gurumurthy; Geetha Ramachandran; A K Hemanth Kumar; S Rajasekaran; C Padmapriyadarsini; Soumya Swaminathan; S Bhagavathy; P Venkatesan; L Sekar; A Mahilmaran; N Ravichandran; P Paramesh Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191
Authors: M A Espinal; S J Kim; P G Suarez; K M Kam; A G Khomenko; G B Migliori; J Baéz; A Kochi; C Dye; M C Raviglione Journal: JAMA Date: 2000-05-17 Impact factor: 56.272
Authors: Debra Benator; Mondira Bhattacharya; Lorna Bozeman; William Burman; Antonino Cantazaro; Richard Chaisson; Fred Gordin; C Robert Horsburgh; James Horton; Awal Khan; Christopher Lahart; Beverly Metchock; Constance Pachucki; Llewellyn Stanton; Andrew Vernon; M Elsa Villarino; Yong Chen Wang; Marc Weiner; Stephen Weis Journal: Lancet Date: 2002-08-17 Impact factor: 79.321
Authors: R Ridzon; C G Whitney; M T McKenna; J P Taylor; S H Ashkar; A T Nitta; S M Harvey; S Valway; C Woodley; R Cooksey; I M Onorato Journal: Am J Respir Crit Care Med Date: 1998-06 Impact factor: 21.405